Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-cash Items (2016 - 2022)

Ani Pharmaceuticals (ANIP) has disclosed Non-cash Items for 8 consecutive years, with $3.9 million as the latest value for Q4 2022.

  • Quarterly Non-cash Items fell 43.0% to $3.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2022, down 43.0% year-over-year, with the annual reading at $3.9 million for FY2022, 43.0% down from the prior year.
  • Non-cash Items hit $3.9 million in Q4 2022 for Ani Pharmaceuticals, down from $6.8 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $6.8 million in Q4 2021 to a low of $372000.0 in Q4 2020.
  • Historically, Non-cash Items has averaged $4.0 million across 5 years, with a median of $3.9 million in 2022.
  • Biggest five-year swings in Non-cash Items: plummeted 94.5% in 2020 and later surged 1724.19% in 2021.
  • Year by year, Non-cash Items stood at $2.2 million in 2018, then skyrocketed by 204.41% to $6.8 million in 2019, then tumbled by 94.5% to $372000.0 in 2020, then soared by 1724.19% to $6.8 million in 2021, then tumbled by 43.0% to $3.9 million in 2022.
  • Business Quant data shows Non-cash Items for ANIP at $3.9 million in Q4 2022, $6.8 million in Q4 2021, and $372000.0 in Q4 2020.